Eli Lilly & Company: Oral Obesity Prescription Tracker
Institutional-grade analysis used by equity desks before repricing events. 11 pages.
Report fact snapshot
- Publisher
- JPMorgan
- Date
- 2026-06-21
- Type
- Company Report
- Region
- United States
- Companies
- North America Equity Research, June, Eli Lilly, Jun
Market is pricing this as noise.
Data shows a structural shift is underway.
Sector models are broken — re-rating is imminent.
Based on JPMorgan research, June 2026 data and regional breakdowns
Key Signals
Market is pricing this as noise.
Data shows a structural shift is underway.
Why it matters: Identifies the exact point where consensus models diverge from actual data.
A re-rating catalyst is approaching.
Consensus has not yet reflected this shift.
Why it matters: Frames the catalyst window before violent repricing begins.
Winners are concentrated in this space.
Specific companies are structurally outperforming.
Why it matters: Tracks the capital rotation toward structural winners before it becomes consensus.
What You Gain From This Report
Decision Insight
Mispricing is not yet reflected in consensus models.
Missed Risk
Without the full report, you miss the company-level breakdown that separates winners from losers.
Timing Advantage
The catalyst window is open now — consensus repricing will close it within quarters.
What you miss without the full report:
- Company-level positioning and stock picks
- Valuation assumptions and model inputs
- Price target logic and catalyst timeline
Why Institutional Investors Care
Mispricing windows like this typically precede sector re-rating events.
Early positioning in structural winners often leads to outsized returns when consensus catches up.
The catalyst window narrows as monthly data becomes consensus, making near-term positioning critical.
Report Summary
Chris Schott, CFA AC North America Equity Research (1-212) 622-5676 19 June 2026 JPMORGAN [email protected] the company pages of our client website, http://www.jpmorganmarkets.com . This report also sets out within it the material underlying History of Investment Recommendations: A history of J.P. Morgan investment recommendations disseminated during the preceding 12 months can be accessed on the Research & Commentary page of http://www.jpmorganmarkets.com where you can also search by analyst name, sector or financial instrument. Analysts' Compensation:The research analysts responsible for the preparation of this report receive compensation based u
Institutional Content Below
Full PDF (11 pages), valuation models, broker logic, and detailed charts.
Key Takeaways
- Weekly TRx for the obesity market grew ~79% / ~499k TRx YoY looking
- Zepbound TRx were up ~59% YoY, translating to +240k weekly TRx for
- Looking at low-dose NRx of Zepbound (as a proxy for new patient starts),
- Please note that there has been a data capture issue (starting the week
- The Oral Wegovy launch is off to a solid start and appears market
- Oral Wegovy has launched well with ~161.5k TRx / 132.9k NRx as of the
Topics Covered
Companies Mentioned
Who this summary is for
This summary is for users researching the JPMorgan Eli Lilly & Company report. It helps users review Eli Lilly & Company: Oral Obesity Prescription Tracker coverage, key takeaways, and related broker or sector research paths across Lilly, Company:, Oral; North America Equity Research, June.
Related Search Paths
Use these links to continue through broker, sector and report-type research summaries.
Request Full PDF Access
Get access to the full broker report, including company-level details, valuation assumptions, charts, and price target logic.
Access is provided through VIP service or request confirmation.